UnknownNot Applicable

Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity

France300 participantsStarted 2021-06-10

Plain-language summary

A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi syndrome is the only genetic obesity identified to date associated with hyperghrelinemia, while ghrelin levels are lower than in controls in other situations of obesity. The aim of the study is to find out whether the levels of ghrelin, which are abnormally high in PWS throughout life, are also high in these RD when people have hyperphagia and/or overweight.

Who can participate

Age range3 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with one of the following rare diseases associated with : Angelman syndrome, Smith-Magenis syndrome, X Fragile syndrome, rare diseases of the cerebellum, rare epilepsies, PW-like syndromes or other rare diseases with eating disorders * Patients aged minimum 3 years and maximum 50 years. * Patients with overweight (or obesity) and/or hyperphagic behavior. Exclusion Criteria: * Administrative problems: impossibility of giving parents or legal guardians informed information ; no coverage by a Social Security scheme.

What they're measuring

Levels of ghrelin in blood sample

Timeframe: Day 1

Trial details

NCT IDNCT04768803

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-15

Contact for this trial

Nadege ALGANS

0561777204 algans.n@chu-toulouse.fr

View on ClinicalTrials.gov More Angelman Syndrome trials